Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Letermovir was approved by the Food and Drug Administration (FDA) in November 2017 for use in adult cytomegalovirus (CMV)-seropositive allogeneic stem cell transplant (SCT) recipients for primary prophylaxis of CMV infection and disease. We report off-label use of letermovir for secondary prophylaxis of genotype-confirmed ganciclovir-resistant cytomegalovirus (CMV) syndrome (UL 97 mutation [C603W]) in a heart transplant recipient initially treated with intravenous cidofovir followed by foscarnet, both discontinued due to unacceptable toxicities.

Original languageEnglish (US)
JournalTransplant Infectious Disease
DOIs
StateAccepted/In press - Jan 1 2018

Keywords

  • Cytomegalovirus
  • Ganciclovir resistance
  • Heart transplant
  • Letermovir
  • UL97 mutation

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation)'. Together they form a unique fingerprint.

  • Cite this